It’s A Tremendous Trilobite Tuesday! 

This massive virus with its own immune system could hold the future of medicine

French researchers think they’ve found a giant virus big enough to house its own virus-killing devices using a system like CRISPR, and it could be a completely new form of life.

Called a mimivirus, it was first found growing in amoebae in a water tower. At four times the size of a typical virus, you can even see it under a light microscope

When the mimivirus encounters another virus, it stores some of the invader’s genetic material. That way, when it encounters the same kind of virus again, the MIMIVIRE system goes into gene-editing berserker mode, finding the key genes of the virus and cutting them to inert oblivion. This could have major applications.

Follow @the-future-now​

Largest Batch of Earth-size, Habitable Zone Planets

Our Spitzer Space Telescope has revealed the first known system of seven Earth-size planets around a single star. Three of these planets are firmly located in an area called the habitable zone, where liquid water is most likely to exist on a rocky planet.

This exoplanet system is called TRAPPIST-1, named for The Transiting Planets and Planetesimals Small Telescope (TRAPPIST) in Chile. In May 2016, researchers using TRAPPIST announced they had discovered three planets in the system.

Assisted by several ground-based telescopes, Spitzer confirmed the existence of two of these planets and discovered five additional ones, increasing the number of known planets in the system to seven.

This is the FIRST time three terrestrial planets have been found in the habitable zone of a star, and this is the FIRST time we have been able to measure both the masses and the radius for habitable zone Earth-sized planets.

All of these seven planets could have liquid water, key to life as we know it, under the right atmospheric conditions, but the chances are highest with the three in the habitable zone.

At about 40 light-years (235 trillion miles) from Earth, the system of planets is relatively close to us, in the constellation Aquarius. Because they are located outside of our solar system, these planets are scientifically known as exoplanets. To clarify, exoplanets are planets outside our solar system that orbit a sun-like star.

In this animation, you can see the planets orbiting the star, with the green area representing the famous habitable zone, defined as the range of distance to the star for which an Earth-like planet is the most likely to harbor abundant liquid water on its surface. Planets e, f and g fall in the habitable zone of the star.

Using Spitzer data, the team precisely measured the sizes of the seven planets and developed first estimates of the masses of six of them. The mass of the seventh and farthest exoplanet has not yet been estimated.

For comparison…if our sun was the size of a basketball, the TRAPPIST-1 star would be the size of a golf ball.

Based on their densities, all of the TRAPPIST-1 planets are likely to be rocky. Further observations will not only help determine whether they are rich in water, but also possibly reveal whether any could have liquid water on their surfaces.

The sun at the center of this system is classified as an ultra-cool dwarf and is so cool that liquid water could survive on planets orbiting very close to it, closer than is possible on planets in our solar system. All seven of the TRAPPIST-1 planetary orbits are closer to their host star than Mercury is to our sun.

 The planets also are very close to each other. How close? Well, if a person was standing on one of the planet’s surface, they could gaze up and potentially see geological features or clouds of neighboring worlds, which would sometimes appear larger than the moon in Earth’s sky.

The planets may also be tidally-locked to their star, which means the same side of the planet is always facing the star, therefore each side is either perpetual day or night. This could mean they have weather patterns totally unlike those on Earth, such as strong wind blowing from the day side to the night side, and extreme temperature changes.

Because most TRAPPIST-1 planets are likely to be rocky, and they are very close to one another, scientists view the Galilean moons of Jupiter – lo, Europa, Callisto, Ganymede – as good comparisons in our solar system. All of these moons are also tidally locked to Jupiter. The TRAPPIST-1 star is only slightly wider than Jupiter, yet much warmer. 

How Did the Spitzer Space Telescope Detect this System?

Spitzer, an infrared telescope that trails Earth as it orbits the sun, was well-suited for studying TRAPPIST-1 because the star glows brightest in infrared light, whose wavelengths are longer than the eye can see. Spitzer is uniquely positioned in its orbit to observe enough crossing (aka transits) of the planets in front of the host star to reveal the complex architecture of the system. 

Every time a planet passes by, or transits, a star, it blocks out some light. Spitzer measured the dips in light and based on how big the dip, you can determine the size of the planet. The timing of the transits tells you how long it takes for the planet to orbit the star.

The TRAPPIST-1 system provides one of the best opportunities in the next decade to study the atmospheres around Earth-size planets. Spitzer, Hubble and Kepler will help astronomers plan for follow-up studies using our upcoming James Webb Space Telescope, launching in 2018. With much greater sensitivity, Webb will be able to detect the chemical fingerprints of water, methane, oxygen, ozone and other components of a planet’s atmosphere.

At 40 light-years away, humans won’t be visiting this system in person anytime soon…that said…this poster can help us imagine what it would be like: 

Make sure to follow us on Tumblr for your regular dose of space: http://nasa.tumblr.com

Quote by #rosalindfranklin How do you make science a part of your life? What are you doing to fight for scientific literacy? More quotes and questions in my #ilovescience journal. #womeninscience #scientificliteracy

Today is UN International Day of Women and Girls in Science!

We’ve pulled together this collection of quotes from inspiring women who have made huge contributions in their scientific fields.

Please share this inspiration!

After the four new additions, here’s a look at the origins of all the element names in the periodic table! High-res image/PDF: http://wp.me/p4aPLT-1Ru

Also featured in The Conversation UK alongside an article from Professor Mark Lorch here: https://goo.gl/g60pGU

Life Continues Within the Body After Death, Evidence Shows

The body keeps working to repair itself after death, according to a provocative new study that could offer insight into how we might put the big sleep on hold.

Even after someone is declared dead, life continues in the body, suggests a surprising new study with important implications.

Gene expression — when information stored in DNA is converted into instructions for making proteinsor other molecules — actually increases in some cases after death, according to the new paper, which tracked postmortem activity and is published in the journal Open Biology.

“Not all cells are ‘dead’ when an organism dies,” senior author Peter Noble of the University of Washington and Alabama State University told Seeker. “Different cell types have different life spans, generation times and resilience to extreme stress.”  

In fact, some cells seem to fight to live after the organism has died.

“It is likely that some cells remain alive and are attempting to repair themselves, specifically stem cells,” Noble said.

After Centuries, Scientists Have Finally Figured Out How Water Conducts Electricity

One of life's most fundamental processes has been witnessed.

It’s a textbook moment centuries in the making: more than 200 years after scientists started investigating how water molecules conduct electricity, a team has finally witnessed it happening first-hand.

It’s no surprise that most naturally ocurring water conducts electricity incredibly well - that’s a fact most of us have been taught since primary school. But despite how fundamental the process is, no one had been able to figure out how it actually happens on the atomic level.

“This fundamental process in chemistry and biology has eluded a firm explanation,” said one of the team, Anne McCoy from the University of Washington. “And now we have the missing piece that gives us the bigger picture: how protons essentially ‘move’ through water.”

Continue Reading.

It’s nearly the season of the witch: time for some cauldron chemistry

Midwives and nurses sometimes came under suspicion because of their specialised knowledge and success - or failure - in treating those who were sick. These healing roles were traditionally taken on by women who, until around the turn of the nineteenth century, were excluded from formal medical training. However, many still practiced medicine in their homes and villages, and what they had learned came from shared knowledge and trial and error, rather than accepted official sources. A medical education might not have been a great help in any case. In the days before germ theory the causes of sickness and the reasons for recovery were not obvious. Any recoveries could be seen as miraculous … or the result of witchcraft.

Treating sickness and disease pre-germ theory was largely guesswork. All sorts of noxious compounds were administered to ailing individuals, and if they produced any effect on the body, be it vomiting, diarrhoea or sweating, it was seen as a good thing – and that was the practice of the so-called professionals. It is not hard to see how images of unofficial healers and herbalists (both men and women) stooping over boiling pots of herbs, roots and who-knows-what, could become a template for the image of a witch, especially when many of the concoctions they produced had such unpleasant effects on their patients.

Having said that, herbalists and traditional healers should not be dismissed as completely ignorant of the medical benefits of some of the plants and poultices they used. Some of the ingredients associated with traditional healing and witches’ potions have been found to be hugely beneficial to medicine once they have been isolated, tested and modified. Science has enabled us to identify the key components of some plants and test them to determine how and when they should be administered safely and effectively. Chemists have modified the structures of some of the compounds to reduce side-effects, make drugs more potent or lower their toxicity.

‪The first synthesis of aspirin was carried out #OTD in 1897. Here’s a look at how it compares to other painkillers: http://www.compoundchem.com/2014/09/25/painkillers/‬

Manufacturing Dopamine in the Brain with Gene Therapy

Parkinson’s patients who take the drug levodopa, or L-Dopa, are inevitably disappointed. At first, during a “honeymoon” period, their symptoms (which include tremors and balance problems) are brought under control. But over time the drug becomes less effective. They may also need ultrahigh doses, and some start spending hours a day in a state of near-frozen paralysis.

A biotech company called Voyager Therapeutics now thinks it can extend the effects of L-Dopa by using a surprising approach: gene therapy. The company, based in Cambridge, Massachusetts, is testing the idea in Parkinson’s patients who’ve agreed to undergo brain surgery and an injection of new DNA.

Parkinson’s occurs when dopamine-making neurons in the brain start dying, causing movement symptoms that afflicted boxing champ Muhammad Ali and actor Michael J. Fox, whose charitable foundation has helped pay for the development of Voyager’s experimental treatment.

The cause of Parkinson’s isn’t well understood, but the reason the drug wears off is. It’s because the brain also starts losing an enzyme known as aromatic L-amino acid decarboxylase, or AADC, that is needed to convert L-Dopa into dopamine.

Voyager’s strategy, which it has begun trying on patients in a small study, is to inject viruses carrying the gene for AADC into the brain, an approach it thinks can “turn back the clock” so that L-Dopa starts working again in advanced Parkinson’s patients as it did in their honeymoon periods.

Videos of patients before and after taking L-Dopa make it obvious why they’d want the drug to work at a lower dose. In the ‘off’ state, people move in slow motion. Touching one’s nose takes an effort. In an ‘on’ state, when the drug is working, they’re shaky, but not nearly so severely disabled.

“They do well at first but then respond very erratically to L-Dopa,” says Krystof Bankiewicz, the University of California scientist who came up with the gene-therapy plan and is a cofounder of Voyager. “This trial is to restore the enzyme and allow them to be awakened, or ‘on,’ for a longer period of time.”

Voyager was formed in 2013 and later went public, raising about $86 million. The company is part of a wave of biotechs that have been able to raise money for gene therapy, a technology that is starting to pay off: after three decades of research, a few products are reaching the market.

Unlike conventional drug studies, those involving gene therapy often come with very high expectations that the treatment will work. That’s because it corrects DNA errors for which the exact biological consequences are known. Genzyme, a unit of the European drug manufacturer Sanofi, paid Voyager $65 million and promised hundreds of millions more in order to sell any treatments it develops in Europe and Asia.

“We’re working with 60 years of dopamine pharmacology,” says Steven Paul, Voyager’s CEO, and formerly an executive at the drug giant Eli Lilly. “If we can get the gene to the right tissue at the right time, it would be surprising if it didn’t work.”

But those are big ifs. In fact, the concept for the Parkinson’s gene therapy dates to 1986, when Bankiewicz first determined that too little AADC was the reason L-Dopa stops working. He thought gene therapy might be a way to fix that, but it wasn’t until 20 years later that he was able to test the idea in 10 patients, in a study run by UCSF.

In that trial, Bankiewicz says, the gene delivery wasn’t as successful as anticipated. Not enough brain cells were updated with the new genetic information, which is shuttled into them by viruses injected into the brain. Patients seemed to improve, but not by much.

Even though the treatment didn’t work as planned, that early study highlighted one edge Voyager’s approach has over others. It is possible to tag AADC with a marker chemical, so doctors can actually see it working inside patients’ brains. In fact, ongoing production of the dopamine-making enzyme is still visible in the brains of the UCSF patients several years later.

It is possible to tag AADC with a marker chemical, so doctors can actually see it working inside patients’ brains. Image Source: MIT Technology Review.

In some past studies of gene therapy, by contrast, doctors had to wait until patients died to find out whether the treatment had been delivered correctly. “This is a one-and-done treatment,” says Paul. “And anatomically, it tells us if we got it in the right place.”

A new trial under way, this one being carried out by Voyager, is designed to get much higher levels of DNA into patients’ brains in hopes of achieving better results. To do that, Bankiewicz developed a system to inject the gene-laden viral particles through pressurized tubes while a patient lies inside an MRI scanner. That way, the surgeon can see the putamen, the brain region where the DNA is meant to end up, and make sure it’s covered by the treatment.

There are other gene therapies for Parkinson’s disease planned or in testing. A trial developed at the National Institutes of Health seeks to add a growth factor and regenerate cells. A European company, Oxford BioMedica, is trying to replace dopamine.

Altogether, as of this year, there were 48 clinical trials under way of gene or cell replacement in the brain and nervous system, according to the Alliance for Regenerative Medicine, a trade group. The nervous system is the fourth most common target for this style of experimental treatment, after cancer, heart disease, and infections.

Voyager’s staff is enthusiastic about a study participant they call “patient number 6,” whom they’ve been tracking for several months—ever since he got the treatment. Before the gene therapy, he was on a high dose of L-Dopa but still spent six hours a day in an “off” state. Now he’s off only two hours a day and takes less of the drug.

That patient got the highest dose of DNA yet, covering the largest brain area. That is part of what makes Voyager think higher doses should prove effective. “I believe that previous failure of gene-therapy trials in Parkinson’s was due to suboptimal delivery,” says Bankiewicz.

Image Credit: L.A. JOHNSON

Source: MIT Technology Review (by Antonio Regalado)